Therapeutic HPV vaccines

Journal article

High-risk human papillomavirus (HPV) infection is known to be a necessary factor for cervical and anogenital malignancies. Cervical cancers account for over a quarter of a million deaths annually. Despite the availability of prophylactic vaccines, HPV infections remain extremely common worldwide. Furthermore, these vaccines are ineffective at clearing pre-existing infections and associated preinvasive lesions. As cervical dysplasia can regress spontaneously, a therapeutic HPV vaccine that boosts host immunity could have a significant impact on the morbidity and mortality associated with HPV. Therapeutic vaccines differ from prophylactic vaccines in that they are aimed at generating cell-mediated immunity rather than neutralising antibodies. This review will cover various therapeutic vaccine strategies in development for the treatment of HPV-associated lesions and cancers.

Authors: Hancock, G; Hellner, K; Dorrell, L

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Elsevier
• Journal: Best Practice and Research Clinical Obstetrics and Gynaecology
• Volume: 47
• Pages: 59-72
• Publication date: 2017-09-28
• Acceptance date: 2017-09-28
• DOI: 10.1016/j.bpobgyn.2017.09.008
• EISSN: 1532-1932
• ISSN: 1521-6934
• Pmid: 29108943
• Language: English
• Keywords: HPV-Associated malignancies; therapeutic vaccine; bacterial vector; high-risk human papillomavirus; DNA vaccine; viral vector